KBC Group NV, an institutional investor, recently reduced its ownership of Prestige Consumer Healthcare ($NYSE:PBH) Inc. in the first quarter of this year by 10.5%. The move has been seen as a possible indication of a shift in investor sentiment regarding the company. Prestige Consumer Healthcare Inc. is an American multinational consumer packaged goods holding company that manufactures, markets and distributes over-the-counter drugs, nutritional products and personal care products. The company has a long history of value creation and is committed to providing a wide range of products that meet the needs of consumers.
Its portfolio includes well-known brands such as Chloraseptic, Little Remedies, Luden’s, Bodycology, Comet and more. It could also reflect their concerns about the challenges facing the industry in the near future. It is unclear at this time what the long-term effects will be, but it is clear that investors are taking a cautious approach with their investments.
GoodWhale has conducted an analysis of PRESTIGE CONSUMER HEALTHCARE’s wellbeing. According to our Star Chart, PRESTIGE CONSUMER HEALTHCARE is strong in profitability, but weak in asset, dividend and growth. Based on this analysis, we have classified PRESTIGE CONSUMER HEALTHCARE as a ‘sloth’, a type of company which has achieved revenue or earnings growth slower than the overall economy. Given its weak growth and low risk profile, PRESTIGE CONSUMER HEALTHCARE may appeal to investors who are looking for companies that have a steady track record of providing consistent returns. Additionally, PRESTIGE CONSUMER HEALTHCARE has a high health score of 7/10 considering its cashflows and debt, so it is capable to safely ride out any crisis without the risk of bankruptcy. In view of these factors, investors who are looking for stability and reliable returns may be interested in investing in PRESTIGE CONSUMER HEALTHCARE. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for PBH. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PBH. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PBH. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for PBH are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company’s main competitors are Galenica Ltd., Guangdong Kanghua Healthcare Co Ltd, and Mednow Inc.
Galenica Ltd. is a Swiss pharmaceutical company with a market cap of 3.43B as of 2022. The company has a return on equity of 11.13%. Galenica Ltd. is a pharmaceutical company that focuses on the development, production, and marketing of drugs and medical devices.
– Guangdong Kanghua Healthcare Co Ltd ($SEHK:03689)
Kanghua Healthcare is a leading healthcare company in China with a market cap of over $600 million. The company has a strong focus on research and development and has a strong portfolio of products. The company’s return on equity is 4.5%. Kanghua Healthcare is a well-respected company in the healthcare industry and is a great investment for long-term growth.
Mednow Inc is a company that provides medical supplies and services. The company has a market capitalization of $8.63 million and a return on equity of -91.28%. The company’s products and services include medical equipment, supplies, and services. Mednow Inc is headquartered in the United States.
This indicates that KBC Group NV may have lost faith in the performance of Prestige Consumer Healthcare and decided to decrease their investment by distributing a portion of their shares. Investors should take note and pay attention to Prestige Consumer Healthcare’s performance going forward. Additionally, analysts should consider the impact of this decrease in investment on Prestige Consumer Healthcare’s future stock price.